SkinBioTherapeutics plc

Equities

SBTX

GB00BF33H870

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 07:30:00 01/04/2026 BST			5-day change	1st Jan Change
9.750 ^GBX	0.00%		+21.88%	-38.10%

04-01	SkinBioTherapeutics Shares Suspended from Trading Over Delayed Results	MT
04-01	SkinBioTherapeutics says trading in co's shares to be suspended from today	RE

SkinBioTherapeutics plc Reports Earnings Results for the Full Year Ended June 30, 2025

Published on 12/05/2025 at 08:35 am GMT - Modified on 12/05/2025 at 07:00 am GMT

S&P Capital IQ

SKINBIOTHERAPEUTICS PLC

0.00%

SkinBioTherapeutics plc reported earnings results for the full year ended June 30, 2025. For the full year, the company reported sales was GBP 4.64 million compared to GBP 1.21 million a year ago. Net loss was GBP 0.696253 million compared to GBP 2.88 million a year ago.

Basic loss per share from continuing operations was GBP 0.0031 compared to GBP 0.0154 a year ago.

Latest news about SkinBioTherapeutics plc

04-01	SkinBioTherapeutics Shares Suspended from Trading Over Delayed Results	MT
04-01	SkinBioTherapeutics says trading in co's shares to be suspended from today	RE
03-24	WINNERS & LOSERS: S4 Capital surges; Distil mulls funding options	AN
03-20	SkinBioTherapeutics faces April trading suspension until review ends	AN
03-20	SkinBioTherapeutics Expects to Miss Earnings Reporting Deadline, Flags Trading Suspension in London	MT
03-20	SkinBioTherapeutics HY26 results delayed until board investigation is complete	RE
03-20	SkinBioTherapeutics plc Delays Earnings Results Release for the Interim Results for the Six Months Ended December 31, 2025	CI
03-09	SkinBioTherapeutics adds interim CEO Rachel Parsonage to board	AN
03-09	SkinBioTherapeutics appoints Rachel Parsonage, interim CEO, to board of directors	RE
03-09	SkinBioTherapeutics plc Appoints Rachel Parsonage to the Board of Directors	CI
03-02	SkinBioTherapeutics appoints interim CEO as investigation continues	AN
03-02	SkinBioTherapeutics Names Interim CEO	MT
03-02	SkinBioTherapeutics appoints Rachel Parsonage as interim CEO	RE
03-02	Skinbiotherapeutics plc Appoints Rachel Parsonage as Interim CEO, Effective March 2, 2026	CI
02-20	FTSE 100 climbs on strong retail sales data	AN

Chart SkinBioTherapeutics plc

Duration

Period

SBTX: Dynamic Chart

Company Profile

SkinBioTherapeutics plc is a United Kingdom-based life science company focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health, and commercialization of these technologies, as well as the manufacture and sales of dermatological products through acquired entities. Its segments include UK, US, EU, and RoW. Its platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. It targets five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment and pharmaceuticals for the prescribed treatment of skin conditions. Its first product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis-a chronic inflammatory condition of the skin.

Employees

Sector

Biotechnology & Medical Research

More about the company